Combination therapy using anti-EGFR and anti-HER2 antibodies

US9522956B2 · kind B2 · utility

Assignee

• L'Institut National de la Sante et de la Recherche Medicale · FR

Inventors

• Stephen D. Gillies · Carlisle, US
• David Azria · Le Puy-en-Velay, FR
• Christel Larbouret · Castelnau-le-Lez, FR
• Andre Pelegrin · Montpellier, FR

Key dates

• Filing date: Nov 10, 2014
• Grant date: Dec 20, 2016
• Expiry date: Nov 10, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.